CNN: FDA could move closer to approving first new Alzheimer’s drug in nearly 20 years
An important advisory committee in the FDA is set to meet Friday. They will discuss an experimental intravenous treatment for Alzheimer’s called aducanumab. If the treatment is well received by the committee it may become the first immunotherapy for Alzheimer’s and the first treatment to show that removing amyloid beta improves patient outcomes. Click here to read more from J. Howard. Click here to read more about Alzheimer’s.